Who are Window Therapeutics's investors?

Window Therapeutics's investors include ShangBay Capital LLC.

How much funding has Window Therapeutics raised?

Window Therapeutics has disclosed $7.5M raised across 1 round.

Where is Window Therapeutics headquartered?

Window Therapeutics is headquartered in Boston, US.

Window Therapeutics

Boston, US · Founded 2021 · Delaware corporation · 1 known investors

Window Therapeutics is a biotechnology company developing therapeutics for cancer and other life-threatening diseases, based on its bottle-brush-analogue-macromonomer (BAM) technology. The company applies molecular chemistry and biology research, originally developed in the MIT laboratory of Dr. Jeremiah Johnson.

Biotech Deep Tech Healthtech

Founders & leadership

James LuNamed on SEC filing

Jeremiah JohnsonFounder (based on BAM technology from his MIT lab)

Lusong LuoNamed on SEC filing

Chih-Kao HuNamed on SEC filing

Board

Kenneth C. AndersonProfessor, Researcher and Clinician, Harvard Medical School & DFCI

Investors · 1

ShangBay Capital LLCPalo Alto

Reported raises · per SEC filings

Form D private placements

$7.5M disclosed across 1 round · 2023

▶$7.5MraisedOct 2023 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

James LuDirector
Jeremiah JohnsonDirector
Lusong LuoDirector
Kenneth AndersonDirector
Chih-Kao HuExecutive Officer, Director

Offering amount: $7.5M
Amount sold: $7.5M
Minimum investment: $50K
First sale: Sep 2023
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Solu4 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Northwest Biotherapeutics3 shared keywordsNW Bio develops personalized dendritic cell-based cancer vaccines intended to treat a range of solid tumor cancers as an alternative to chemotherapy. Its clinical-stage products target cancers including glioblastoma, inoperable solid tumors, ovarian cancer, and prostate cancer.

Click Therapeutics3 shared keywordsClick Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy. It targets diseases through a platform-based approach applying neuroscience and neuromodulatory mechanisms for patients with unmet medical needs.

Companies competing with Window Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Window Therapeutics do?: Window Therapeutics is a biotechnology company developing therapeutics for cancer and other life-threatening diseases, based on its bottle-brush-analogue-macromonomer (BAM) technology. The company applies molecular chemistry and biology research, originally developed in the MIT laboratory of Dr. Jeremiah Johnson.
Who are Window Therapeutics's investors?: Window Therapeutics's investors include ShangBay Capital LLC.
How much funding has Window Therapeutics raised?: Window Therapeutics has disclosed $7.5M raised across 1 round.
Where is Window Therapeutics headquartered?: Window Therapeutics is headquartered in Boston, US.